Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer

Kim, Min Woo; Niidome, Takuro; Lee, Ruda

doi:10.3390/md17100581

Cited by 35 publications

(18 citation statements)

References 39 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PSL embedding both the hydrophobic rapamycin (RAPA) and the hydrophilic doxorubicin (DOX) were also prepared using glycol chitosan (GC) to achieve the pH-triggered drug release profile [ 121 ] ( Figure 10 ). To this aim, ω-liposomes made of docosahexaenoic acid (DHA) and loaded with RAPA were first prepared by the thin-lipid-film hydration method.…”

Section: Polymer/liposome Assembly To Confer Stimuli-responsive Prmentioning

confidence: 99%

“…The nanovectors are stable at pH 7.4 and aggregate when the pH is lowered to 5.0. Reproduced under Creative Common license from ref [ 121 ].…”

Section: Figures and Schemementioning

confidence: 99%

“…Schematic illustration of liposome containing doxorubicin and rapamycin and complexed with glycol chitosan.The nanovectors are stable at pH 7.4 and aggregate when the pH is lowered to 5.0. Reproduced under Creative Common license from ref[121].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Recent Advancements in Polymer/Liposome Assembly for Drug Delivery: From Surface Modifications to Hybrid Vesicles

2021

View full text Add to dashboard Cite

Liposomes are consolidated and attractive biomimetic nanocarriers widely used in the field of drug delivery. The structural versatility of liposomes has been exploited for the development of various carriers for the topical or systemic delivery of drugs and bioactive molecules, with the possibility of increasing their bioavailability and stability, and modulating and directing their release, while limiting the side effects at the same time. Nevertheless, first-generation vesicles suffer from some limitations including physical instability, short in vivo circulation lifetime, reduced payload, uncontrolled release properties, and low targeting abilities. Therefore, liposome preparation technology soon took advantage of the possibility of improving vesicle performance using both natural and synthetic polymers. Polymers can easily be synthesized in a controlled manner over a wide range of molecular weights and in a low dispersity range. Their properties are widely tunable and therefore allow the low chemical versatility typical of lipids to be overcome. Moreover, depending on their structure, polymers can be used to create a simple covering on the liposome surface or to intercalate in the phospholipid bilayer to give rise to real hybrid structures. This review illustrates the main strategies implemented in the field of polymer/liposome assembly for drug delivery, with a look at the most recent publications without neglecting basic concepts for a simple and complete understanding by the reader.

show abstract

Section: Polymer/liposome Assembly To Confer Stimuli-responsive Prmentioning

confidence: 99%

“…The nanovectors are stable at pH 7.4 and aggregate when the pH is lowered to 5.0. Reproduced under Creative Common license from ref [ 121 ].…”

Section: Figures and Schemementioning

confidence: 99%

See 1 more Smart Citation

Recent Advancements in Polymer/Liposome Assembly for Drug Delivery: From Surface Modifications to Hybrid Vesicles

2021

View full text Add to dashboard Cite

show abstract

“…Passive targeting can be accomplished by increasing the affinity of SCs to the target tissue while relying on diffusion and circulation to do the work of carrying them to the tissue. In these cases, the surface of SCs can be modified with polymers, protein ligands, or antibodies that increase their targeting specificity (De Leo et al, 2018; J. Cao et al, 2018; Kim et al, 2019). When multiple targeting moieties are used, the specificity of the targeting increases (Gray et al, 2013; P. Guo et al, 2019; Nikkhoi et al, 2018; S. Oliveira et al, 2010; Qu et al, 2014).…”

Section: Applications Of Synthetic Cellsmentioning

confidence: 99%

Synthetic cells in biomedical applications

Sato

Zajkowski

Moser³

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Synthetic cells are engineered vesicles that can mimic one or more salient features of life. These features include directed localization, sense‐and‐respond behavior, gene expression, metabolism, and high stability. In nanomedicine, many of these features are desirable capabilities of drug delivery vehicles but are difficult to engineer. In this focus article, we discuss where synthetic cells offer unique advantages over nanoparticle and living cell therapies. We review progress in the engineering of the above life‐like behaviors and how they are deployed in nanomedicine. Finally, we assess key challenges synthetic cells face before being deployed as drugs and suggest ways to overcome these challenges. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials > Lipid‐Based Structures

show abstract

“…Lee et al designed GC-docosahexaenoic acid (GC-DHA) liposomes that could deliver DOX and rapamycin (RAPA) for the treatment of drug-resistant breast tumor. [141] RAPA is a specific inhibitor of the mammalian target of rapamycin (mTOR), which is related to PI3K-Akt signaling-based cell proliferation. In combination treatment of DOX with RAPA, the therapeutic sensitivity and efficacy could be enhanced against various types of tumor by inhibiting mTOR signaling.…”

Section: Recent Advances In Theranostic Cnps For Cancer Heterogeneitymentioning

confidence: 99%

Tumor‐Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity

et al. 2020

View full text Add to dashboard Cite

liposomes (Doxil; liposomal doxorubicin (DOX), Onivyde; liposomal irinotecan, Vyxeos; liposomal daunorubicin plus cytarabine) and albumin nanoparticles (Abraxane; albumin nanoparticle-bound paclitaxel), being approved for clinical use and other nanocarriers being at different stages of clinical development. [2] Despite recent research and development of nanomedicines, the success rate of clinical translation remains poor, with patients in clinical settings benefitting from nanomedicines only through a reduction in side effects. [3] This is primarily because the enhanced accumulation of nanoparticles at tumor sites was initially overvalued in preclinical settings, with insufficient consideration given to tumor heterogeneity and complexity. [4] An analysis of studies published from 2005 to 2015 on the efficiency of nanoparticle delivery found that only 0.7% of the administered dose of nanoparticles was delivered to the tumor, irrespective of the materials, targeting strategy, hydrodynamic diameter, zeta potential, shape of nanoparticles, tumor model, and cancer type. [5] This low efficiency of delivery has prompted investigations to determine whether any key factors were omitted in the design and development of nanocarriers. A fundamental understanding of the key factors determining the tumor-targeting ability of nanoparticles is therefore required to optimize the design and development of nanoparticles with enhanced efficiency of delivery to tumors. Although many studies have assessed the impact of nanocarrier properties on the efficiency of targeted delivery, the effects of different factors are interconnected and often in opposition. For example, coating the surfaces of nanocarriers with poly(ethylene glycol) (PEG) extends their circulation in the blood by minimizing their detection by the immune system, thus contributing to targeted accumulation. However, PEG also reduces the uptake of nanocarriers by tumor tissue or tumor cells, reducing the accumulation of nanocarriers in tumors. Therefore, integrated analysis of the key factors found in a single type of nanoparticle with excellent tumor-targeting ability may provide insights into the entire procedure of developing new tumor-targeting nanocarriers. The relatively moderate therapeutic efficacy of nanomedicines in clinical settings may be due in part to tissue heterogeneity. The clinical benefits of nanomedicines have been reported to be highly variable and limited compared with their Nanomedicine is extensively employed for cancer treatment owing to its unique advantages over conventional drugs and imaging agents. This increased attention to nanomedicine, however, has not fully translated into clinical utilization and patient benefits due to issues associated with reticuloendothelial system clearance, tumor heterogeneity, and complexity of the tumor microenvironment. To address these challenges, efforts are being made to modify the design of nanomedicines, including optimization of their physiochemical properties, active targeting, and response to stimuli, but...

show abstract

Glycol Chitosan-Docosahexaenoic Acid Liposomes for Drug Delivery: Synergistic Effect of Doxorubicin-Rapamycin in Drug-Resistant Breast Cancer

Cited by 35 publications

References 39 publications

Recent Advancements in Polymer/Liposome Assembly for Drug Delivery: From Surface Modifications to Hybrid Vesicles

Recent Advancements in Polymer/Liposome Assembly for Drug Delivery: From Surface Modifications to Hybrid Vesicles

Synthetic cells in biomedical applications

Tumor‐Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity

Contact Info

Product

Resources

About